ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ALXO · as of Sep 30, 2025
Ownership Breakdown
63
Institutional Holders
$51.27M
Total Inst. Value
▲ $38.70M vs Q2
134.56M
Shares Outstanding
freeFloat 79.53%
27.79M
13F Shares Held
▼ 1.29M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ALXO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VENBIO PARTNERS LLC pharmaceutical preparations | 9.70M | 18.15% | 18.15% | $17.75B | Nov 14, 2025 | — held |
REDMILE GROUP, LLC pharmaceutical preparations | 3.33M | 6.24% | 6.24% | $6.10B | Nov 14, 2025 | ▼ 58.5K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 2.62M | 4.91% | 4.91% | $4.80B | Nov 14, 2025 | ▲ 2.13M |
ALMITAS CAPITAL LLC pharmaceutical preparations | 2.54M | 4.75% | 4.75% | $4.64B | Nov 17, 2025 | ▼ 1.5K |
VANGUARD GROUP INC pharmaceutical preparations | 1.53M | 2.86% | 2.86% | $2.80B | Nov 7, 2025 | ▼ 72.2K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 1.22M | 2.28% | 2.28% | $2.23B | Nov 13, 2025 | ▼ 47.2K |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 795.8K | 1.49% | 1.49% | $1.46B | Nov 14, 2025 | NEW |
TWO SIGMA ADVISERS, LP pharmaceutical preparations | 719.8K | 1.35% | 1.35% | $1.32B | Nov 14, 2025 | ▲ 16.5K |
AMERIPRISE FINANCIAL INC pharmaceutical preparations | 652.9K | 1.22% | 1.22% | $1.19B | Nov 14, 2025 | NEW |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 606.7K | 1.14% | 1.14% | $1.11B | Nov 14, 2025 | ▲ 128.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+2.48M shares6
New Positions
first time holders24
Decreased
−1.92M shares0
Sold Out
fully exitedNet shares change (top 50)
+559.2K
+2.48M / −1.92M
Net new holders
-8
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ALXO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Knight Jeff E. Chief Dev & Operating Officer | Apr 16, 2026 | Award | 800,000 | $1.68 | $1.34M | 800.0K | Form 4 ↗ |
Klencke Barbara Chief Medical Officer | Apr 16, 2026 | Award | 100,000 | $1.68 | $168.0K | 100.0K | Form 4 ↗ |
Lettmann Jason CHIEF EXECUTIVE OFFICER | Mar 19, 2026 | Sale | 12,311 | $2.17 | $26.7K | 293.6K | Form 4 ↗ |
Pinto Shelly SVP, FINANCE AND CAO | Mar 19, 2026 | Sale | 903 | $2.17 | $2.0K | 86.8K | Form 4 ↗ |
Klencke Barbara Chief Medical Officer | Mar 3, 2026 | Award | 700,000 | $2.07 | $1.45M | 700.0K | Form 4 ↗ |
Pinto Shelly SVP, FINANCE AND CAO | Feb 18, 2026 | Sale | 565 | $2.27 | $1.3K | 87.7K | Form 4 ↗ |
Lettmann Jason CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Tax Withhold | 2,201 | $2.27 | $5.0K | 305.9K | Form 4 ↗ |
GOODMAN COREY S
| Feb 2, 2026 | Purchase | 3,184,713 | $1.57 | $5.00M | 8.45M | Form 4 ↗ |
Shantharam Harish Chief Financial Officer | Jan 26, 2026 | Award | 303,000 | $1.48 | $448.4K | 303.0K | Form 4 ↗ |
Pinto Shelly SVP, FINANCE AND CAO | Jan 26, 2026 | Award | 192,000 | $1.48 | $284.2K | 192.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ALX Oncology Holdings Inc. (ALXO) is primarily owned by institutional investors, who hold approximately 20.6% of total shares outstanding. Company insiders own approximately 20.47%, while retail and public investors account for the remaining 58.88%.
The largest institutional shareholder of ALX Oncology Holdings Inc. is VENBIO PARTNERS LLC, holding approximately 9.70 million shares — equal to 18.15% of outstanding shares — as of September 30, 2025.
A total of 63 institutional investors currently hold ALXO stock, with a combined institutional value of approximately $51,273,440 as of the most recent 13F filing period.
Frequently asked questions
ALXO ownershipALX Oncology Holdings Inc. (ALXO) is primarily owned by institutional investors, who hold approximately 20.6% of shares. The largest shareholder is VENBIO PARTNERS LLC with a 18.15% stake. Company insiders hold 20.47%. Data sourced from SEC Form 13F as of September 30, 2025.